NASDAQ$RMTI

Rockwell Medical Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Reported record net sales and gross profit, and raised 2024 guidance.

Rockwell Medical reported record net sales of $22.7 million for Q1 2024, a 15% increase year-over-year. Gross profit also reached a record $3.1 million, up 18% from the same period last year. The company has raised its full-year 2024 guidance for net sales, gross profit, and adjusted EBITDA.

  • Net sales increased by 15% year-over-year, reaching $22.7 million.
  • Gross profit increased by 18% year-over-year, reaching $3.1 million.
  • The company has revised its guidance for 2024 upward.
  • Rockwell Medical was certified as a Great Place to Work® for the second year in a row.

Headline financials

Total Revenue

$22.7M

Previous: $19.7M+15.3%
EPS

-$0.06

Previous: -$0.10+40.0%
Gross Margin

14.0%

No prior period
Adjusted EBITDA

-$529K

No prior period
Adjusted EPS

-$0.02

No prior period
Capital Expenditures

-$139K

Previous: -$145K+4.1%
Free Cash Flow

-$1.73M

Previous: -$1.9M+8.7%
Net Income

-$1.73M

Previous: -$1.75M+1.1%
Operating Income

-$1.32M

Previous: -$1.43M+7.2%
Gross Profit

$3.06M

Previous: $2.6M+17.9%
Cash & Equivalents

$6.64M

Previous: $10.9M-39.0%
Total Assets

$50.7M

Previous: $40.5M+25.3%
R&D Expense

$18K

No prior period
Stock-Based Comp

$251K

Previous: $193K+30.1%

Revenue & EPS history

Rockwell Medical · Revenue · Quarterly

$22.7M

Q1 2024+15.3%vs Q1 2023
Beat estimate in 8 of 13 quarters(62%)
ActualEstimate

Forward guidance

Rockwell Medical updated its guidance for the full year 2024, projecting net sales between $90.0M and $94.0M, gross profit between $13.0M and $15.0M, and adjusted EBITDA between $0.5M and $1.0M.

Tailwinds

  • Net Sales: $90.0M to $94.0M (13% to 18% increase over 2023)
  • Gross Profit: $13.0M to $15.0M (49% to 72% increase over 2023)
  • Gross Margin: 4 to 6 percentage point increase over 2023
  • Adjusted EBITDA: $0.5M to $1.0M (113% to 126% increase over 2023)
  • Net sales to grow in the mid-to-high single digits in 2025 and beyond.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-3.1%

Avg return

Earnings day

-3.3%

Avg return

5 days after

-3.0%

Avg return

30 days after

38%

24 / 63 earnings

Positive

+28.2%

Q3 2022

Best reaction

-43.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-13.0%-11.3%
Q1 2026-3.6%+2.8%-18.2%
Q3 2025-9.2%-17.1%-12.4%
Q1 2025-6.4%-9.8%-11.6%
Q4 2024-20.5%-31.8%-41.5%
Q3 2024-43.4%-49.2%-55.5%
Q2 2024+22.6%+35.6%+68.4%
Q1 2024+0.6%+4.1%+8.2%
Q4 2023+3.6%+0.0%-12.1%
Q3 2023+12.2%+5.1%-11.2%
Q2 2023-7.4%-25.8%-28.5%
Q1 2023-4.5%-3.7%+71.8%
Q4 2022+14.6%+18.4%+74.7%
Q3 2022+28.2%+19.4%+0.0%
Q2 2022+12.0%+7.1%-14.1%
Q1 2022+3.0%-17.3%-34.7%
Q4 2021-13.6%-11.4%-27.3%
Q3 2021-7.7%-7.7%-21.2%
Q2 2021-6.2%-10.8%-4.6%
Q1 2021-2.2%-4.3%+0.0%
Q4 2020+4.5%-1.8%-13.5%
Q3 2020+1.1%+5.6%+33.7%
Q2 2020+4.2%+0.0%-26.3%
Q1 2020-4.7%-12.9%-9.0%
Q4 2019-42.7%-25.0%-22.6%
Q3 2019+5.4%+12.4%+23.7%
Q2 2019-5.6%+2.0%+9.3%
Q1 2019-7.5%-11.9%-25.6%
Q4 2018+3.0%+23.9%+4.7%
Q3 2018+8.9%+12.3%-16.2%
Q2 2018-15.5%-12.4%-13.6%
Q1 2018-2.5%+5.8%-8.8%
Q4 2017-17.5%-18.3%-14.1%
Q3 2017+9.6%+11.6%+3.4%
Q2 2017-4.2%-1.5%-5.4%
Q1 2017-1.2%-9.1%+9.3%
Q4 2016+10.0%+10.2%+10.6%
Q3 2016-20.5%-3.5%+27.3%
Q2 2016-8.9%-8.1%-10.2%
Q1 2016+19.7%
Q4 2015-36.8%
Q3 2015-10.5%
Q2 2015+11.5%
Q1 2015+12.9%
Q4 2014-6.6%
Q3 2014+5.7%
Q2 2014+0.1%
Q1 2014-8.5%
Q3 2013-0.8%
Q2 2013+0.6%
Q1 2013-7.6%
Q4 2012-19.9%
Q3 2012-3.3%
Q2 2012-6.4%
Q1 2011-0.2%
Q1 2012+1.0%
Q4 2011-4.4%
Q3 2011-9.3%
Q3 2010-9.3%
Q2 2011-0.1%
Q2 2010-0.1%
Q4 2010-1.4%
Q1 2010+3.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro